Amplia Therapeutics Ltd (ATX)

Currency in AUD
0.205
+0.020(+10.81%)
Closed·
ATX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ATX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1900.205
52 wk Range
0.0490.425
Key Statistics
Bid/Ask
0.20 / 0.205
Prev. Close
0.185
Open
0.19
Day's Range
0.19-0.205
52 wk Range
0.049-0.425
Volume
5.01M
Average Volume (3m)
7.83M
1-Year Change
58.45%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.420
Upside
+104.88%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Amplia Therapeutics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Amplia Therapeutics Ltd Company Profile

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Compare ATX to Peers and Sector

Metrics to compare
ATX
Peers
Sector
Relationship
P/E Ratio
−15.0x−4.6x−0.5x
PEG Ratio
−1.94−0.020.00
Price/Book
4.7x2.6x2.6x
Price / LTM Sales
26.1x13.3x3.3x
Upside (Analyst Target)
104.9%306.7%43.5%
Fair Value Upside
Unlock14.8%6.8%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.420
(+104.88% Upside)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
2.38M / --
EPS Revisions
Last 90 days

ATX Income Statement

People Also Watch

3.950
DRO
-3.42%
0.770
MTM
+4.05%
2.240
ELS
+1.36%
0.150
BOT
+3.45%

FAQ

What Stock Exchange Does Amplia Therapeutics Trade On?

Amplia Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Amplia Therapeutics?

The stock symbol for Amplia Therapeutics is "ATX."

What Is the Amplia Therapeutics Market Cap?

As of today, Amplia Therapeutics market cap is 99.73M.

What Is Amplia Therapeutics's Earnings Per Share (TTM)?

The Amplia Therapeutics EPS (TTM) is -0.02.

From a Technical Analysis Perspective, Is ATX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Amplia Therapeutics Stock Split?

Amplia Therapeutics has split 4 times.

How Many Employees Does Amplia Therapeutics Have?

Amplia Therapeutics has 0 employees.

What is the current trading status of Amplia Therapeutics (ATX)?

As of 09 Aug 2025, Amplia Therapeutics (ATX) is trading at a price of 0.21, with a previous close of 0.19. The stock has fluctuated within a day range of 0.19 to 0.21, while its 52-week range spans from 0.05 to 0.43.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.